- Home
- LXEH vs BGLC Comparison
LXEH vs BGLC Comparison
Compare LXEH & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- BGLC
- Stock Information
- Founded
- LXEH 2001
- BGLC 2017
- Country
- LXEH China
- BGLC Malaysia
- Employees
- LXEH N/A
- BGLC N/A
- Industry
- LXEH Other Consumer Services
- BGLC Medical Specialities
- Sector
- LXEH Real Estate
- BGLC Health Care
- Exchange
- LXEH Nasdaq
- BGLC Nasdaq
- Market Cap
- LXEH 5.7M
- BGLC 5.8M
- IPO Year
- LXEH 2020
- BGLC N/A
- Fundamental
- Price
- LXEH $4.92
- BGLC $0.38
- Analyst Decision
- LXEH
- BGLC
- Analyst Count
- LXEH 0
- BGLC 0
- Target Price
- LXEH N/A
- BGLC N/A
- AVG Volume (30 Days)
- LXEH 105.0K
- BGLC 10.9M
- Earning Date
- LXEH 03-15-2025
- BGLC 02-20-2025
- Dividend Yield
- LXEH N/A
- BGLC N/A
- EPS Growth
- LXEH N/A
- BGLC N/A
- EPS
- LXEH N/A
- BGLC N/A
- Revenue
- LXEH $5,628,870.00
- BGLC $9,259,858.00
- Revenue This Year
- LXEH N/A
- BGLC N/A
- Revenue Next Year
- LXEH N/A
- BGLC N/A
- P/E Ratio
- LXEH N/A
- BGLC N/A
- Revenue Growth
- LXEH N/A
- BGLC N/A
- 52 Week Low
- LXEH $1.95
- BGLC $0.21
- 52 Week High
- LXEH $65.06
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- LXEH 53.73
- BGLC 59.27
- Support Level
- LXEH $4.70
- BGLC $0.33
- Resistance Level
- LXEH $5.45
- BGLC $0.41
- Average True Range (ATR)
- LXEH 0.51
- BGLC 0.11
- MACD
- LXEH -0.14
- BGLC 0.01
- Stochastic Oscillator
- LXEH 26.64
- BGLC 23.68
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.